Drug Discovery at Emory

For decades, Emory University has been at the forefront of discovering treatments for diseases of global concern. In the 1990s, it was HIV. Then, cancer and hemophilia. Today, it's COVID-19. What remains constant is the commitment of our researchers to improve the health and lives of all.

A Brief History of Drug Innovation
Latest News

December 23, 2021
The U.S. Food and Drug Administration (FDA) announced that molnupiravir, an investigational oral antiviral drug invented by scientists at Emory University, has received Emergency Use Authorization (EUA) for treatment of COVID-19.

The EUA authorizes the use of molnupiravir for “the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate.”

View more News

The Little Pill That Could

Molnupiravir, a promising weapon against COVID-19, was being developed years before the world faced the onslaught of a virus that has killed more than 5 million people in fewer than 24 months. Researcher George Painter looms large in the creation of molnupiravir and the history of drug discovery at Emory. 

Read more about George Painter and the Discovery of Molnupiravir
george painter poses outside with blurred green leaves behind him

How Molnupiravir Works


Molnupiravir 101

Fact Sheet

Experts Talk about Molnupiravir

What They Said

What Drives Them?

Many Emory researchers have spent the better part of their lives dedicated to discovering and developing drug treatments for some of today’s most challenging diseases—and those yet to emerge. In this video, our scientists talk about that moment “they live for” and what spurs them despite setbacks and failures.

Drug Discovery at Emory: Tackling Confounding Diseases and Conditions

Gregory L. Fenves, President, Emory University

Jonathan S. Lewin, EVP for Health Affairs, Emory University

Deborah W. Bruner, SVP, Research, Emory University

Media Contact

Emory Media Relations